Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1689-1697

  Rosen, Fred R ^a   Haraf, Daniel J ^d   Kies, Merrill S ^b   Stenson, Kerstin ^d   Portugal, Louis ^a   List, Marcy A ^d   Brockstein, Bruce E ^d   Mittal, Bharat B ^b   Rademaker, Alfred W ^c   Witt, Mary Ellyn ^d   Pelzer, Harold ^c   Weichselbaum, Ralph R ^d   Vokes, Everett E ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; HYDROXYUREA; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CONTROL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; INFUSION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037652181     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Calais, G., Alfonsi, M., Bardet, E., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., Oudinot, P., and Bertrand, P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. (Bethesda), 91: 2081-2086, 1999.
2. Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., and Prosnitz, L. R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med., 338: 1798-1804, 1998.
3. Wendt, T. G., Grabenbauer, G. G., Rodel, C. M., Thiel, H. J., Aydin, H., Rohloff, R., Wustrow, T. P., Iro, H., Popella, C., and Schalhorn, A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol., 16: 1318-1324, 1998.
4. Pignon, J. P., Bourhis, J., Domenge, C., and Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet, 355: 949-955, 2000.
5. Forastiere, A., Koch, W., Trotti, A., and Sidransky, D. Head and neck cancer. N. Engl. J. Med., 345: 1890-1900, 2001.
6. Vokes, E. E., Panje, W. R., Schilsky, R. L., Mick, R., Awan, A. M., Moran, W. J., Goldman, M. D., Tybor, A. G., and Weichselbaum, R. R. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a Phase I-II study. J. Clin. Oncol., 7: 761-768, 1989.
7. Garden, A. S., Pajak, T. F., Vokes, E., Forastiere, A., Ridge, J., Jones, C., Horwitz, E., Nabell, L., Glisson, B., Cooper, J. S., Demas, W., and Gore, E. Preliminary results of RTOG 9703: a Phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 223a, 2001.
8. Vokes, E. E., Kies, M. S., Haraf, D. J., Stenson, K., List, M., Humerickhouse, R., Dolan, M. E., Pelzer, H., Sulzen, L., Witt, M. E., Hsieh, Y. C., Mittal, B. B., and Weichselbaum, R. R. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J. Clin. Oncol., 18: 1652-1661, 2000.
9. Kies, M. S., Haraf, D. J., Rosen, F., Stenson, K., List, M., Brockstein, B., Chung, T., Mittal, B. B., Pelzer, H., Portugal, L., Rademaker, A., Weichselbaum, R., and Vokes, E. E. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J. Clin. Oncol., 19: 1961-1969, 2001.
10. Overgaard, J., Hansen, H. S., Jorgensen, K., and Hjelm Hansen, M. Primary radiotherapy of larynx and pharynx carcinoma: an analysis of some factors influencing local control and survival. Int. J. Radiat. Oncol. Biol. Phys., 12: 515-521, 1986.
11. Henry, D. H. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract., 4: 180-184, 1996.
12. Brockstein, B., Haraf, D. J., Stenson, K., Sulzen, L., Witt, M. E., Weichselbaum, R. W., and Vokes, E. E. A Phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann. Oncol., 11: 721-728, 2000.
13. Adelstein, D. J., Saxton, J. P., Lavertu, P., Rybicki, L. A., Esclamado, R. M., Wood, B. G., Strome, M., and Carroll, M. A. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J. Clin. Oncol., 20: 1405-1410, 2002.
14. Sunwoo, J. B., Herscher, L. L., Kroog, G. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Solomon, B. I., Boss, C., Albert, P. J., McCullugh, L., et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J. Clin. Oncol., 19: 800-811, 2001.
15. Boyd, T. S., Harari, P. M., Tannehill, S. P., Voytovich, M. C., Hartig, G. K., Ford, C. N., Foote, R. L., Campbell, B. H., and Schultz, C. J. Planned postradiotherapy neck dissection in patients with advanced head and neck cancer. Head Neck, 20: 132-137, 1998.
16. Sanguineti, G., Corvo, R., Benasso, M., Margarino, G., Sormani, M., Roncallo, F., Mereu, P., Bacigalupo, A., and Vitale, V. Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer. Head Neck, 21: 223-228, 1999.
17. Vokes, E. E., Rosen, F. R., Kies, M. S., List, M. A., Rademaker, A., Stenson, K., Brockstein, B. E., Portugal, L., Mittal, B. B., Pelzer, H., Argiris, A., Williams, R. D., Weichselbaum, R. R., and Haraf, D. J. Weekly carboplatin and paclitaxel followed by concomitant T-FHX chemoradiotherapy for advanced head and neck cancer: a potentially successful strategy. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 21: 230a, 2002.
18. Dubray, B., Mosseri, V., Brunin, F., Jaulerry, C., Poncet, P., Rodriguez, J., Brugere, J., Point, D., Giraud, P., and Cosset, J. M. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology, 201: 553-558, 1996.
19. Haddad, R., Suntharalingam, M., Chen, T., Levy, S., and Vanecho, D. A. Pretreatment hemoglobin is associated with response to chemoradiation therapy in patients with advanced unresectable squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 417a, 2000.
20. Budach, V. G., Haake, K., Stueben, G., Sack, H., Jahnke, K-D., Baumann, M., Hermann, T., Budach, W., Bamberg, M., Sauer, R., Hinkelbein, W., Frommhold, H., and Wernecke, K-D. Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone: two year's results of a German multicenter randomized trial (aro 95-6). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 224a, 2001.
21. Staar, S., Rudat, V., Stuetzer, H., Dietz, A., Volling, P., Schroeder, M., Flentje, M., Eckel, H. E., and Mueller, R. P. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 50: 1161-1171, 2001.
22. Dunphy, F. R., Harrison, B. R., Dunleavy, T. L., Rodriguez, J. J., and Hilton, J. G. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer (Phila.), 86: 1362-1367, 1999.
23. Glaser, C., Millesi, W., and Wanschitz, B. R-HuERythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy improves cancer free survival of patient with oral squamous cell carcinoma: a 17 month follow up. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 399a, 1999.
24. List, M., Haraf, D., Stracks, J., Brockstein, B., Kies, M., Rosen, F., and Vokes, E. Quality of life/performance in head and neck cancer: comparison between paclitaxel-based and cisplatin-based concomitant chemoradiotherapy regimens. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 412a, 2000.
25. Merlano, M., Benasso, M., Corvo, R., Rosso, R., Vitale, V., Blengio, F., Numico, G., Margarino, G., Bonelli, L., and Santi, L. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J. Natl. Cancer Inst. (Bethesda), 88: 583-589, 1996.
26. Adelstein, D. J., Adams, G. L., Li, Y., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., and Forastiere, A. A. A Phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 411a, 2000.
27. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N. Engl. J. Med., 324: 1685-1690, 1991.
28. Lefebvre, J. L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., and Sahmoud, T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancer Inst. (Bethesda), 88: 890-899, 1996.
29. Paccagnella, A., Orlando, A., Marchiori, C., Zorat, P. L., Cavaniglia, G., Sileni, V. C., Jirillo, A., Tomio, L., Fila, G., and Fede, A. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl. Cancer Inst. (Bethesda), 86: 265-272, 1994.
30. Kies, M. S., Haraf, D. J., Athanasiadis, I., Kozloff, M., Mittal, B., Pelzer, H., Rademaker, A. W., Wenig, B., Weichselbaum, R. R., and Vokes, E. E. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J. Clin. Oncol., 16: 2715-2721, 1998.
31. Domenge, C., Hill, C., Lefebvre, J. L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br. J. Cancer, 83: 1594-1598, 2000.
32. Posner M. R., Colevas A. D., and Tishler R. B. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin. Oncol., 27 (Suppl. 8): 13-24, 2000.